FORE Biotherapeutics Announces Oral Presentation of Phase 1/2a Plixorafenib Data at the Society for Neuro-Oncology 2023 Annual Meeting
FORE Biotherapeutics today announced an oral presentation highlighting updated Phase 1/2a clinical data for plixorafenib (FORE8394; PLX8394), the company’s novel, investigational, small-molecule, next-generation, orally available selective inhibitor of BRAF alterations, will be given at the Society for Neuro-Oncology (SNO) 2023 Annual Meeting, taking place November 15-19, 2023, in Vancouver, Canada. The data being presented continue to demonstrate that plixorafenib has a favorable safety profile and results in durable responses in adults with primary central nervous system tumors with BRAF V600 alterations.
Details for the SNO 2023 Oral Presentation:
Title: Efficacy of BRAF inhibitor plixorafenib (FORE8394) in recurrent, primary central nervous system tumors (PCNST)
Presenter: Macarena I. de la Fuente, MD, University of Miami, Sylvester Comprehensive Cancer Center
Abstract number: CTNI-76
Session: Clinical Trials – Non-immunologic
Presentation date and time: Friday, Nov 17, 2023, 3:55-4:05 p.m. PT
About Plixorafenib (FORE8394)
Plixorafenib is an investigational, novel, small-molecule, next-generation, orally available selective inhibitor of mutated BRAF. It was designed to target a wide range of BRAF mutations while sparing wild-type forms of RAF. Nonclinical studies and clinical trials have shown that its unique mechanism of action effectively inhibits not only the constitutively active BRAF V600 monomers targeted by first-generation BRAF inhibitors but also disrupts constitutively active dimeric non-V600 BRAF alterations (class 2 mutants, fusions, splice variants and others). Unlike first- and second-generation BRAF inhibitors, plixorafenib does not induce paradoxical activation of the MAPK pathway. This not only yields the potential for an improved safety profile, but also avoids the need to combine with a MEK inhibitor. As a “paradox breaker,” plixorafenib could therefore yield improved safety and more durable efficacy than earlier generation BRAF inhibitors and have activity in settings of acquired resistance to current RAF inhibitors.
Plixorafenib is currently being evaluated in Phase 1/2a clinical trial in adults and children with advanced solid tumors (including brain and spinal cord tumors) with activating BRAF alterations. Interim clinical data presented at ESMO 2022, ASCO 2023, and SNO 2023 provide evidence of durable anti-tumor single-agent activity in patients with BRAF-mutated cancers.
About Fore Biotherapeutics
Fore Bio is a precision oncology company dedicated to developing innovative treatments that provide a better outcome for cancer patients. Its lead asset plixorafenib (FORE8394) is a V600 and non-V600 BRAF inhibitor with manageable clinical safety and early efficacy signals in an ongoing Phase 1/2a clinical trial. The Fore Bio research and development team is optimizing drug development by identifying existing compounds with known clinical profiles and a clear path through clinical development to advance new medicines for patients without treatment options. For more information, please visit www.fore.bio or follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231110438808/en/
Contact information
Investors and Media:
Argot Partners
212.600.1902|ForeBio@argotpartners.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Capcom Reveals Dragon’s Dogma 2 Scheduled to Launch March 22, 2024!29.11.2023 02:00:00 CET | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that Dragon’s Dogma 2, the latest game in the Dragon’s Dogma series, is scheduled to be released on March 22, 2024. With the launch of Dragon’s Dogma 2, Capcom closes out a stellar year of major title releases for its 2023 fiscal year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231128898951/en/ Dragon's Dogma 2 is a single player, narrative driven action-RPG and the latest title in the Dragon’s Dogma series. The game features intricately crafted, gorgeous visuals powered by Capcom’s proprietary RE ENGINE that elevate its unique gameplay experience to provide a truly immersive fantasy world sure to delight both newcomers as well as long-time fans of the series. (Graphic: Business Wire) Dragon’s Dogma 2 is the latest title in the series, and the first mainline entry since the original Dragon’s Dogma was released in 2012. The game is being developed on Capcom’s proprietary RE EN
Rocket Software to Acquire OpenText’s Application Modernization and Connectivity Business28.11.2023 22:20:00 CET | Press release
Rocket Software, Inc. (“Rocket Software”), a global technology leader driving modernization for the world’s largest companies, today announced it has signed a definitive agreement to acquire the Application Modernization and Connectivity business (AMC) of OpenText (NASDAQ: OTEX), (TSX: OTEX), which was formerly part of Micro Focus. The total purchase price is $2.275B. For decades, Rocket Software has been the partner solving complex IT challenges for the largest and most innovative organizations, across infrastructure, data, and applications. Rocket Software’s hybrid cloud strategy empowers customers to optimize their application portfolio wherever they are in their modernization journey, enabling them to bridge the gap to modern use cases without disrupting their mission-critical operations. This approach allows organizations to benefit from the mainframe's security and dependability while also taking advantage of powerful analytics tools in the cloud. AMC has been a leader in applica
NetApp and AWS Deliver a Nine Times Performance Increase for Amazon FSx for NetApp ONTAP28.11.2023 22:05:00 CET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, announced at re:Invent, scale-out FSx for ONTAP® file systems through its collaboration with AWS. Scale-out file systems offer up to nine times higher storage performance compared to existing file systems, enabling customers to run high-performance applications on AWS more quickly and efficiently. FSx for ONTAP enables customers to use ONTAP’s data management features for a wide variety of workloads, such as user and application file shares, relational databases (SAP HANA), data stores for VMware cloud on AWS and backup and disaster recovery. With the new enhancements, customers can now use FSx for ONTAP for a broader range of higher-performance use cases, such as high-performance computing (HPC), electronic design automation (EDA), visual effects (VFX) and film editing, life sciences, seismic analysis, machine learning, and generative AI. Organizations of all sizes are migrating on-premises workloads to AWS or deploy
Varberg Energi Selects Hansen to Power Intraday Trading28.11.2023 20:50:00 CET | Press release
Hansen Technologies (ASX:HSN), a leading global provider of software and services to the energy, water and communications industries, is pleased to announce Varberg Energi, a Swedish energy company, as a new Hansen customer. Varberg Energi, which has recently added physical-trading operations and balance responsibility to its services, will leverage Hansen Trade to enable this. The intraday trading solution within Hansen Trade will allow Varberg Energi to automate intraday trading operations and balance management. With Hansen Trade as part of its everyday operating infrastructure, Varberg Energi will be able to take advantage of physical trading operations without the need to spend significant time and effort on manual operations. Jens Nordberg, Head of Energy Trading, Varberg Energi, commented: “We have recently made a strategic decision to insource physical-trading operations and balance responsibility. Combined with our flexibility portfolio, we believe that this will create the ri
Abu Dhabi’s Advanced Technology Research Council launches ‘AI71’: New AI Company Pioneering Decentralised Data Control for Companies & Countries28.11.2023 18:16:00 CET | Press release
In an era of rapid advancements across artificial intelligence (AI), Abu Dhabi’s Advanced Technology Research Council (ATRC) is making yet another bold stride with the launch of its new AI company, AI71. The entity builds on the Technology Innovation Institute’s (TII) Falcon generative AI models and will focus on multi-domain specializations while offering unprecedented AI data control options for companies and countries looking to self-host for greater privacy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231128549220/en/ H.H. Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council launches AI71 along with H.E Faisal Al Bannai, Secretary General, Advanced Technology Research Council (Photo: AETOSWire) The new AI powerhouse was launched by H.H. Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Cou